- Home
- DTSQ vs CNTX Comparison
DTSQ vs CNTX Comparison
Compare DTSQ & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- CNTX
- Stock Information
- Founded
- DTSQ 2022
- CNTX 2015
- Country
- DTSQ United States
- CNTX United States
- Employees
- DTSQ N/A
- CNTX N/A
- Industry
- DTSQ
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSQ
- CNTX Health Care
- Exchange
- DTSQ NYSE
- CNTX Nasdaq
- Market Cap
- DTSQ 91.7M
- CNTX 78.0M
- IPO Year
- DTSQ 2024
- CNTX 2021
- Fundamental
- Price
- DTSQ $10.39
- CNTX $0.74
- Analyst Decision
- DTSQ
- CNTX Strong Buy
- Analyst Count
- DTSQ 0
- CNTX 5
- Target Price
- DTSQ N/A
- CNTX $5.50
- AVG Volume (30 Days)
- DTSQ 775.0
- CNTX 163.6K
- Earning Date
- DTSQ 01-01-0001
- CNTX 08-06-2025
- Dividend Yield
- DTSQ N/A
- CNTX N/A
- EPS Growth
- DTSQ N/A
- CNTX N/A
- EPS
- DTSQ 0.28
- CNTX N/A
- Revenue
- DTSQ N/A
- CNTX N/A
- Revenue This Year
- DTSQ N/A
- CNTX N/A
- Revenue Next Year
- DTSQ N/A
- CNTX N/A
- P/E Ratio
- DTSQ $37.10
- CNTX N/A
- Revenue Growth
- DTSQ N/A
- CNTX N/A
- 52 Week Low
- DTSQ $9.96
- CNTX $0.49
- 52 Week High
- DTSQ $10.47
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- CNTX 64.15
- Support Level
- DTSQ N/A
- CNTX $0.62
- Resistance Level
- DTSQ N/A
- CNTX $0.67
- Average True Range (ATR)
- DTSQ 0.00
- CNTX 0.05
- MACD
- DTSQ 0.00
- CNTX 0.02
- Stochastic Oscillator
- DTSQ 0.00
- CNTX 71.12
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.